Abstract. Reduced expression of Raf-1 kinase inhibitor protein (RKIP) has been documented in a number of human malignancies, including colorectal carcinoma (CRC). However, despite the importance of hepatic colorectal metastasis (HCM) for the prognosis of CRC patients, no studies have been conducted regarding RKIP expression in HCM tissues or its prognostic significance. The aim of this study was to clarify the relationship between reduced RKIP expression and HCM and to identify independent predictors for recurrent HCM, which will ultimately help identify patients at high risk of developing metastatic recurrence. An immunohistochemical study of RKIP expression was performed using primary CRC and/or corresponding HCM tissue samples obtained from 117 patients. Forty-nine of these patients did not harbor HCM and 68 harbored HCM. RKIP expression was reduced in 24.5% (12/49) of CRCs without HCM, 47.1% (32/68) of CRCs with HCM and 67.6% (46/68) of HCM. This distribution of RKIP downregulation was statistically significant. RKIP expression was found to independently predict recurrent HCM, with a higher relative risk (6.661) compared to that of nodal metastasis (4.690). A reduction of RKIP expression in HCM was a significant predictor of poor prognosis. The median survival of patients with reduced RKIP expression was 35 months, compared with more than 10 years in patients with positive RKIP expression. Multivariate survival analysis demonstrated that RKIP expression in HCM was an independent predictor of overall survival, with a hazard ratio of 5.161, a value comparable to the risk associated with advanced TNM stage (5.247). We demonstrated that a reduction of RKIP expression in HCM had an independent predictive value for metastatic recurrence and less favorable clinical outcomes in patients with HCM. Our results strongly suggest that patients harboring HCM with reduced RKIP expression require careful monitoring after hepatic resection to detect potentially resectable metastatic recurrences.
Introduction
Colorectal carcinogenesis is a complex multistep process involving progressive disruption of intestinal epithelial cell proliferation, apoptosis, differentiation and survival mechanisms (1) . The extracellular signal-regulated kinase (ERK) pathway is one of the most important pathways for intestinal cell proliferation and differentiation. In this pathway, ERK is activated upon phosphorylation by mitogen-activated protein kinase/ERK kinase (MEK), which itself is activated when phosphorylated by Raf-1. There is growing evidence that activation of the Raf-1/MEK/ERK signaling pathway is involved in the pathogenesis, progression and oncogenic behavior of human colorectal carcinoma (CRC) (2) . The activated ERK pathway in CRC plays a role in cell proliferation through dysregulation of the cell cycle, angiogenesis through enhancing the expression of vascular endothelial growth factor and cell migration and invasion through induction of proteolytic enzymes, such as matrix metalloproteinases (3) .
Raf-1 kinase inhibitory protein (RKIP), also known as phosphatidylethanolamine-binding protein 1, was originally identified as an endogenous inhibitor of Raf-1, and it negatively regulates the Raf-1/MEK/ERK signaling pathway (4) . RKIP suppresses the metastatic spread of tumor cells; moreover, reduced expression of RKIP is observed in a number of human malignancies (5) . In addition to its pivotal role in regulating cell differentiation, cycle and migration, evidence also suggests that RKIP potentiates the apoptosis of tumor cells induced by chemotherapy or radiotherapy (6, 7) . In vitro studies demonstrated that ectopic RKIP overexpression sensitizes DNA-damaging agent-resistant carcinoma cells to undergo apoptosis and can allow tumor cells to be eliminated by host cytotoxic lymphocytes (6, 8) . Furthermore, restoration of RKIP expression in metastatic prostate carcinoma cells is associated with decreased in vitro cell invasion, decreased development of lung metastases in vivo and decreased vascular invasion in the primary tumor (9) . These data suggest that the attenuation of RKIP in tumor cells represents an underlying molecular mechanism of tumor progression and metastasis.
The liver is the most common organ of distant metastases from CRC. Untreated patients with hepatic colorectal metastasis (HCM) have poor prognoses, with a median survival of Reduced Raf-1 kinase inhibitor protein expression predicts less favorable outcomes in patients with hepatic colorectal metastasis HYUN (10) . In contrast, surgical resection of HCM can offer long-term survival and cure in patients with HCM; a 5-year survival rate of 25-39% after hepatic resection has been reported (11) . Therefore, hepatic resection currently represents the best potentially curative treatment for HCM. Unfortunately, however, 60-70% of patients undergoing hepatic resection for HCM will develop recurrences of the disease, most of which are identified in the first 12-18 months postoperatively (12) . Of these, one third will have recurrent metastases isolated to the liver. Since hepatic resection has become safer through improvements in surgical techniques and perioperative management, repeat hepatic resection is more frequently performed in patients with isolated HCM (13) . Repeat hepatic resection for recurrent HCM in carefully selected patients appears warranted in view of reasonable survival expectations that approach that of single hepatic resection (14) . In this regard, there is a need for criteria based on biological determinants for the stratification of patients better and earlier according to their risk of recurrence and survival and, consequently, for the selection of patients who may benefit from repeat hepatic resection. The aim of this study was to evaluate RKIP expression in HCM tissues and to determine whether there is an association between RKIP expression and clinicopathological characteristics and outcome of patients with HCM. In addition, independent predictors for recurrent HCM and their combinations were identified, leading to the identification of patients at high risk of developing metastatic recurrence.
Materials and methods
Patients and tissue specimens. Human CRC tissue samples were obtained from 117 consecutive patients who underwent surgery at the Kyung Hee University Hospital, including 68 patients with HCM and 49 patients without HCM. In the patients with HCM, the corresponding metastatic tissue samples from the same patient were also examined. All the 68 patients with HCM had to meet the following criteria to be considered a candidate for hepatic resection with intent for cure: i) no signs of extrahepatic metastases found in preoperative studies, including chest roentgenography, abdominal ultrasonography and abdominopelvic computed tomography; ii) HCMs such that adequate-sized, well-vascularized hepatic remnants would remain after resection; iii) the patient was medically fit for major hepatic resection. Only patients whose metastases were resectable on presentation were included.
Two independent pathologists reviewed all hematoxylin and eosin-stained slides and selected the most representative slide from each case to perform immunohistochemical staining. Clinicopathological data, including age; gender; location and size of the primary tumor; histological grade; pathological tumor stage (pT); the presence of nodal metastasis and/or HCM; local recurrence; TNM stage; the presence of lymphovascular invasion; size, number and distribution of the metastatic tumor; and postoperative follow-up, were assessed. All tumors were assessed for histological grade according to the World Health Organization classification (15) , and were postoperatively staged according to the seventh edition of the American Joint Committee on Cancer staging system (16 . Nuclei were counterstained with hematoxylin. Slides were subsequently dehydrated following a standard procedure and sealed with coverslips. In order to minimize interassay variation, positive and negative control samples were included in each run. The positive control sample was normal colonic mucosa, and the negative control was prepared by substituting non-immune serum for antibody.
Evaluation of immunohistochemical staining. Immunohistochemical RKIP expression was analyzed with a semi-quantitative scoring method, as described in previous studies (17) (18) (19) (20) (21) (22) . The score is the sum of the percentage of positive tumor cells (0, none; 1, <25%; 2, 25-49%; and 3, ≥50%) and the staining intensity (0, negative; 1, weak; 2, moderate; and 3, strong). Specimens with sums between 0 and 2 were scored as negative, sums of 3 and 4 were scored as weakly positive, and sums of 5 and 6 were scored as positive. All slides were examined and scored by two independent pathologists, who were blinded to the clinicopathological data and patient identity. Disagreements between the two pathologists were resolved by consensus.
Statistical analysis. The χ 2 test or Fisher's exact test was performed to compare RKIP expression between each pair of groups and to determine whether RKIP expression is associated with the clinicopathological characteristics. Multivariate logistic regression analysis with a backward stepwise elimination method was used to identify independent predictors for recurrent HCM. The logistic regression equation also indicated the probability of developing recurrent HCM based on the combination of independent predictors. Univariate and multivariate survival analyses were used to examine the prognostic significance of RKIP expression. Cancer-specific survival was defined as the interval from surgery to the death of the patient due to CRC. Loss to follow-up, death from a cause other than carcinoma and survival until the end of the follow-up period were considered censoring events. The survival curves were drawn according to the Kaplan-Meier method and differences were analyzed by applying the logrank test for univariate survival analysis. Multivariate survival analysis was performed using the Cox proportional hazard model (95% confidence interval) with a backward stepwise elimination method. All covariates with statistical significance in univariate analysis were entered into the multivariate analysis. The least significant covariates were then removed from the model by backward stepwise elimination. Statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as a P-value of <0.05.
Results

Patient demographics and clinicopathological characteristics.
The median age of patients was 61 (range, 33-81); 51.3% (60/117) were 61 or older. There were 77 men and 40 women. Of 68 patients with HCM, 40 (58.8%) patients had died at the time of last follow-up, with the median time to death from hepatic resection of 36 months (range 5-144 months). Median follow-up of survivors was 44 months. Other baseline clinicopathological characteristics of the 117 CRC patients are shown in Table I .
Immunohistochemical RKIP expression in CRC and HCM tissues and its association with clinicopathological characteristics. RKIP immunoreactivity was found to be predominantly cytoplasmic, although weak nuclear staining was noted in a few cells. RKIP expression was observed in tumor cells and in normal epithelial cells of the peritumoral colonic mucosa. RKIP expression was not detectable in the extracellular matrix or in the connective tissues.
Intense RKIP immunostaining was observed in normal colonic epithelia (Fig. 1A) , whereas RKIP expression was reduced in tumor tissue, as expected based on results from previous studies (18, 23) . In CRC without HCM cases, RKIP expression was positive in 75.5% (37/ Fig. 1D ) of the samples. This decrease of RKIP expression in HCM cases compared with the corresponding primary CRC with HCM was also statistically significant (P<0.001), suggesting that the metastatic process in CRC involves a reduction of RKIP expression. None of the clinicopathological characteristics was associated with RKIP expression in HCM (Table II) .
Association of clinicopathological characteristics and RKIP expression with recurrent HCM.
The presence of nodal metastasis (P= 0.015) and vascular invasion (P= 0.045), a higher number (P=0.034) and bilobar distribution (P=0.048) of metastatic tumor and reduced RKIP expression (P= 0.022) were associated with the recurrence of HCM (Table III) . Of these five covariates entered into multivariate logistic regression analysis, nodal metastasis (P= 0.029), number of metastatic tumor (P=0.001) and RKIP expression (P=0.010) were found to independently predict recurrent HCM. Interestingly, reduction of RKIP expression showed a higher relative risk of recurrent HCM (6.661) than that of nodal metastasis (4.690). In addition, when combining the three independent predictors, the subgroup of node-negative patients with multiple HCMs and reduced RKIP expression had the greatest probability of developing recurrent HCM (96% ; Table IV) . Node-positive patients with single HCM were divided into two subgroups according to RKIP expression status; the patients with reduced RKIP expression had a much higher probability of developing recurrent HCM (74%) than patients with positive RKIP expression (39%). Similarly, the node-negative/multiple HCMs/ RKIP-reduced subgroup had a higher probability of developing recurrent HCM (84%) than the node-negative/multiple HCMs/RKIP-positive subgroup (52%). The probability of developing metastatic recurrence in the node-negative/single HCM/RKIP-reduced subgroup (48%) was also higher than in the node-negative/single HCM/RKIP-positive subgroup (11%).
Influence of reduced RKIP expression on survival.
Adequate clinical follow-up information was available for all 68 HCM patients. Univariate analysis for survival revealed that an advanced TNM stage (P= 0.008), the presence of lymphatic (P= 0.008) and vascular invasion (P= 0.028), a higher number (P= 0.001) and bilobar distribution (P= 0.047) of metastatic tumor, the recurrence of HCM (P= 0.001) and reduced RKIP expression (P=0.009) were significant predictors of poor prognosis (Table V) . The median survival of patients with reduced RKIP expression was 35 months, compared with >10 years in patients with positive RKIP expression (Fig. 2) . KaplanMeier plots showed that patients with RKIP-positive HCM had relatively stable survival rates of 75.0% between two and four years after surgery and survival of 62.5% after four years. In contrast, patients with reduced RKIP expression in HCM experienced a steady decline in survival during the entire observation period. The 1-, 3-and 5-year survival rates were 87.8, 49.8 and 37.6% for patients with RKIP-reduced HCM and 100.0, 75.0 and 62.5% for patients with RKIP-positive HCM, respectively (Fig. 2) . Analysis by a multivariate Cox proportional hazard model was performed using TNM stage, lymphatic invasion, number and distribution of metastatic tumor, RKIP expression, vascular invasion and recurrent HCM as covariates. The first five of these covariates were independent prognostic factors, which influenced survival (Table V) . This analysis also demonstrated that reduced RKIP expression in HCM was associated with a significant hazard ratio of 5.161, a value comparable to the risk associated with an advanced TNM stage (5.247).
Discussion
RKIP is a widely expressed and highly conserved cytoplasmic protein, which is reduced in a number of human malignancies, including malignant melanoma and carcinomas of the prostate, breast, liver, gallbladder, pancreas, extrahepatic bile duct, stomach, ovary, uterine cervix and nasopharynx (19, 20, 22, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . In these tumors, reduced RKIP expression is associated with an advanced stage, lymphovascular invasion, metastasis and recurrence and/or poor patient outcome. This suggests that RKIP serves as a prognostic marker and has potential as a molecular determinant of invasion and metastasis. Recently, some investigators have also reported reduction of RKIP expression in CRC and an association between reduced RKIP expression and the presence of nodal and distant metastases, metastatic recurrence and lower survival rates (18, 23, 34) . However, despite the importance of HCM for the prognosis of CRC patients, no studies have been conducted regarding RKIP expression in HCM tissues or its prognostic significance. Recurrence occurs in up to 70% of patients following hepatic resection for HCM, with the most common site being the liver. Approximately 25% of these patients have recurrence only in the liver and therefore may be suitable candidates for repeat hepatic resection (35) . Previous studies have indicated that repeat hepatic resection for recurrent HCM yields comparable results to the first hepatic resection in terms of survival and operative mortality and morbidity (14, 36) . Therefore, the ability to predict the risk of metastatic recurrence in HCM patients is of paramount importance because it may allow the identification of patients who should be monitored frequently and who could benefit from repeat hepatic resection. In this study, the combination of nodal metastasis, number of metastatic tumors and RKIP expression in HCM provided independent predictive information on the recurrence of HCM. These results agree with data from a large-scale study demonstrating that the presence of nodal metastasis and the multiplicity of HCM were independent predictors of poor outcome in HCM patients, and could be used as criteria for predicting metastatic recurrence (11) . Surprisingly, in this study, the probability of developing recurrent HCM in patients with nodal metastasis, multiple HCMs and reduced RKIP expression was 96%. In addition, the relative risk of recurrent HCM associated with reduction of RKIP expression was higher than the risk associated with nodal metastasis. Combined analysis of the independent predictors confirmed that the status of RKIP expression influences the probability of developing metastatic recurrence independent of nodal metastasis and number of metastatic tumor. Taken together, these results suggest that RKIP expression in CRC is a strong and novel predictive marker for the identification of patients at high risk of developing recurrent HCM and can be used as one of the criteria for predicting metastatic recurrence after hepatic resection in patients with HCM.
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RKIP expression in HCM were associated with a shorter survival in HCM patients. There was a strong relationship between RKIP expression in HCM and survival even after adjusting for other prognostic parameters in the multivariate analysis, indicating that reduced RKIP expression in HCM is an independent predictor for poor prognosis. The absence of a significant relationship of RKIP expression in HCM with the established clinicopathological characteristics also indicated that RKIP expression in HCM is independent of other conventional prognostic parameters. Although previous studies have also shown RKIP expression to independently predict worse survival in CRC patients (18, 23) , those studies used primary CRC tissues for immunostaining. This study shows that RKIP expression in HCM is an independent predictor for survival of HCM patients and suggests that RKIP expression in HCM can be used as a novel prognostic marker for worse outcome in HCM patients.
We observed that 22 (32.4%) patients with HCM had positive RKIP expression. These findings are similar to data reported by previous studies (20, 22) . There are several possible explanations for these results. First, the mechanisms causing metastasis are complex and multifactorial; a number of signaling pathways other than the ERK pathway can contribute to invasion and metastasis in CRC. Second, protein kinase C-mediated phosphorylation of RKIP results in the dissociation of RKIP from Raf-1 (37) . Third, RKIP selectively impairs the phosphorylation of MEK by Raf-1; RKIP does not prevent the phosphorylation of MEK by kinases other than Raf-1 or by autophosphorylation. A recent study demonstrated that RKIP regulates Raf-1, but not B-Raf, suggesting that B-Raf can activate MEK and ERK independent of RKIP (38). Papin et al reported that B-Raf displayed a higher MEK kinase activity than Raf-1 (39) . In addition to the predominant MEK activators Raf-1 and B-Raf, MEK kinase-1 (MEKK-1) and A-Raf can also phosphorylate MEK, although the biochemical potency of A-Raf is much weaker than that of Raf-1 or B-Raf (40) . Finally, MEK is capable of autophosphorylation, leading to an increase of MEK kinase activity (41) . These possibilities are currently being explored by evaluating the expression of protein kinase C, MEKK-1 and phosphorylated ERK and the mutational status of BRAF gene and by correlating them with RKIP expression in HCM.
Despite increasing evidence that RKIP is lost during tumor progression and especially in metastasis, the mechanism responsible for the downregulation of RKIP has yet to be elucidated. Some have suggested that RKIP promoter methylation is a potential RKIP silencing event, but these results are controversial. Minoo et al described RKIP methylation in a cohort of 12 patients with hyperplastic polyposis coli (42) . In another study using CRC, however, the same authors failed to find RKIP methylation in all 28 cases examined (23). Al-Mulla et al reported that in CRC completely lacking RKIP expression, the promoter region of RKIP was methylated, suggesting that CpG methylation of the RKIP promoter is a possible mechanism by which RKIP is silenced (17) . In contrast, in a study using gastrointestinal stromal tumors, none of the cases without RKIP expression exhibited RKIP promoter methylation (43) . Recently, SNAIL, a zinc finger transcriptional repressor gene, has been shown to bind to the E-box in the RKIP promoter and repress RKIP expression in a metastatic prostate carcinoma cell line (44) . SNAIL is upregulated in human CRC and even more frequently overexpressed in tumors with metastatic ability (45) . Therefore, further investigations exploring the possible association between RKIP and SNAIL in CRC should be performed.
In conclusion, we demonstrated that a reduction of RKIP expression in HCM had an independent predictive value for metastatic recurrence and less favorable clinical outcomes in patients with HCM. Patients harboring HCM with reduced RKIP expression require careful monitoring after hepatic resection for HCM for early detection of potentially resectable metastatic recurrences.
